DYN Dyne Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1818794 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-42.7%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-74.6%
ROA-57.6%
ROIC (approx.)-225.2%
Asset turnover—
Leverage & solvency
Liabilities / assets24.6%
Debt / equity0.21x
Current ratio12.99x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-3.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $398.33M | $281.41M |
| SG&A expense | $69.85M | $62.48M |
| Operating income | -$468.18M | -$343.89M |
| Income tax | $0 | $0 |
| Net income | -$446.21M | -$317.42M |
| EBITDA | -$466.13M | -$342.21M |
| EPS (basic) | -3.47 | -3.37 |
| EPS (diluted) | -3.47 | -3.37 |
| Balance sheet | ||
| Cash & equivalents | $893.37M | $435.45M |
| Short-term investments | $217.19M | $206.82M |
| Current assets | $1.13B | $659.28M |
| PP&E, net | $24.03M | $5.40M |
| Total assets | $1.19B | $691.23M |
| Current liabilities | $50.62M | $42.26M |
| Long-term debt | $148.92M | $0 |
| Total debt | $148.92M | $0 |
| Total liabilities | $214.83M | $61.40M |
| Shareholders' equity | $972.13M | $629.84M |
| Net debt | -$744.45M | -$435.45M |
| Shares outstanding | 164.95M | 102.32M |
| Cash flow statement | ||
| Operating cash flow | -$403.21M | -$292.37M |
| Capital expenditure | $1.92M | $2.38M |
| Free cash flow | -$405.13M | -$294.75M |
| Investing cash flow | -$28.75M | -$204.08M |
| Financing cash flow | $890.31M | $809.89M |
| Depreciation & amortization | $2.05M | $1.67M |
| Stock-based compensation | $45.85M | $45.86M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.